Campylobacter polypeptides and methods of use
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07K-014/205
A61K-039/02
A61K-039/00
A61K-039/108
C07K-014/245
A61K-039/112
C07K-014/255
출원번호
US-0675898
(2012-11-13)
등록번호
US-10086059
(2018-10-02)
발명자
/ 주소
Straub, Darren E.
Emery, Daryll A.
출원인 / 주소
EPITOPIX, LLC
대리인 / 주소
Mueting, Raasch & Gebhardt, PA
인용정보
피인용 횟수 :
0인용 특허 :
43
초록▼
The present invention provides isolated metal regulated polypeptides obtainable from a Campylobacter spp., and compositions including the polypeptides. The present invention also includes methods for using the compositions disclosed herein, including methods for treating in infection in a subject, f
The present invention provides isolated metal regulated polypeptides obtainable from a Campylobacter spp., and compositions including the polypeptides. The present invention also includes methods for using the compositions disclosed herein, including methods for treating in infection in a subject, for treating a condition caused by a Campylobacter spp., and for decreasing colonization of an animal.
대표청구항▼
1. A pharmaceutical composition comprising a Campylobacter jejuni whole cell preparation comprising: an amount of Campylobacter jejuni whole cells sufficient to elicit an immune response to C. jejuni in an animal, wherein the whole cells comprise iron-regulated polypeptides having molecular weights,
1. A pharmaceutical composition comprising a Campylobacter jejuni whole cell preparation comprising: an amount of Campylobacter jejuni whole cells sufficient to elicit an immune response to C. jejuni in an animal, wherein the whole cells comprise iron-regulated polypeptides having molecular weights, as determined by 10% SDS-PAGE, of between 150 kDa and 152 kDa, between 143 kDa and 145 kDa, between 123 kDa and 125 kDa, between 88 kDa and 90 kDa, between 73 kDa and 75 kDa, between 69 kDa and 71 kDa, between 51 kDa and 53 kDa, between 50 kDa and 52 kDa, and between 38 kDa and 40 kDa that are expressed by the C. jejuni whole cells when grown in culture medium comprising 15-20 microgram per ml of 2,2-dipyridyl ; andan effective amount of a pharmaceutically acceptable adjuvant. 2. The composition of claim 1, wherein the whole cells are inactivated whole cells. 3. A method of administering to an animal colonized by or at risk of being colonized by Campylobacter jejuni, an effective amount of a pharmaceutical composition comprising a C. jejuni whole cell preparation comprising: an amount of C. jejuni whole cells effective to decrease colonization of the intestinal tract of the animal by C. jejuni, wherein the whole cells comprise iron-regulated polypeptides having molecular weights, as determined by 10% SDS-PAGE, of between 150 kDa and 152 kDa, between 143 kDa and 145 kDa, between 123 kDa and 125 kDa, between 88 kDa and 90 kDa, between 73 kDa and 75 kDa, between 69 kDa and 71 kDa, between 51 kDa and 53 kDa, between 50 kDa and 52 kDa, and between 38 kDa and 40 kDa that are expressed by the C. jejuni whole cells when grown in culture medium comprising 15-20 microgram per ml of 2,2-dipyridyl; andan effective amount of a pharmaceutically acceptable adjuvant. 4. The method of claim 3, wherein the animal is a mammal or a bird. 5. The method of claim 3, wherein the C. jejuni is C. jejuni ATCC strain PTA-6215. 6. A method of reducing fecal shedding of Campylobacter jejuni in an animal colonized by or at risk of being colonized by C. jejuni, the method comprising administering to the animal an effective amount of a pharmaceutical composition comprising a C. jejuni whole cell preparation comprising: an amount of C. jejuni whole cells effective to decrease fecal shedding of C. jejuni by the animal, wherein the whole cells comprise iron-regulated polypeptides having molecular weights, as determined by 10% SDS-PAGE, of between 150 kDa and 152 kDa, between 143 kDa and 145 kDa, between 123 kDa and 125 kDa, between 88 kDa and 90 kDa, between 73 kDa and 75 kDa, between 69 kDa and 71 kDa, between 51 kDa and 53 kDa, between 50 kDa and 52 kDa, and between 38 kDa and 40 kDa that are expressed by the C. jejuni whole cells when grown in culture medium comprising 15-20 microgram per ml of 2,2-dipyridyl; andan effective amount of a pharmaceutically acceptable adjuvant. 7. The method of claim 6, wherein the animal is a mammal or a bird. 8. The method of claim 6, wherein the C. jejuni is C. jejuni ATCC strain PTA-6215.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (43)
Daryll A. Emery ; Darren E. Straub ; Richard Huisinga ; Beth A. Carlson, Active immunization using a siderophore receptor protein.
Mill Patrick James (Beaconfield EN) Cresswell Michael Alan (High Wycombe EN) Feinberg Joseph George (London EN), Conjugates of acid polysaccharides and complex organic substances.
Potter Andrew A. (Saskatoon CAX) Harland Richard J. (Saskatoon CAX), Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins.
Schryvers Anthony B. (Calgary CAX), Method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of va.
Blake Milan S. (New York NY) Tai Joseph Y. (Fort Washington PA) Qi Huilin L. (New York NY) Liang Shu-Mei (Bethesda MD) Hronowski Lucjan J. J. (Laurel MD) Pullen Jeffrey K. (Columbia MD), Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Ne.
Emery Daryll A. (Willmar MN) Straub Darren E. (Willmar MN) Huisinga Richard (Willmar MN), Method of priming an immune response in a one-day old animal.
Emery,Daryll A.; Straub,Darren E.; Zammert,Donavan E.; Kallevig,Gayla K., Methods for making compositions including gram negative microbial polypeptides.
Cochrum Kent C. (Davis CA) Dorian Randel E. (Orinda CA) Jemtrud Susan A. (San Francisco CA), Multiple layer alginate coatings of biological tissue for transplantation.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.